CA 19.9, Circulating Tumor Cells, Circulating Tumor DNA (KRAS), Pancreatic Adenocarcinoma
Conditions
Keywords
Circulating Tumor Cells, pancreatic adenocarcinoma, circulating tumor DNA (KRAS), CA 19.9
Brief summary
Histological proof is a crucial and necessary step for appropriate care in oncology. In the case of pancreatic cancer, histological proof from pathological analysis of the surgical specimen is very rare due to the limited number (15-20 %) of localized tumor accessible to surgical resection. In most cases, invasive endoscopic explorations are necessary for histological diagnosis before deciding of the most appropriate treatment (palliative chemotherapy or radiochemotherapy). The endoscopic ultrasound with fine needle aspiration (EUS-FNA) is currently considered as the first-line endoscopic procedure for the cytological diagnosis of solid pancreatic tumors. The technique is performed under general anesthesia with sensitivity for the diagnosis of adenocarcinoma of 80% in case of a single procedure and 92% in situations where three different procedures are required. EUS-FNA has to be performed by a physician properly trained for this type of interventional endoscopy. Some severe complications may occur but are relatively rare in expert centers (bleeding, perforation, complications of general anesthesia ...). Diagnostic alternative approach is biological with research in the peripheral blood of markers of tumor disease. It is possible to detect indirect markers which are molecules produced by tumor tissue (eg CA19.9) and direct markers which reflect the presence of tumor biological material (circulating tumor cells (CTCs) or circulating tumor DNA). The value of detection of CTCs is not determined for the diagnostic and therapeutic management of pancreatic cancer. Indeed, no study has evaluated the diagnosis performance of circulating markers with EUS-FNA, the reference method for the diagnosis of unresectable forms.
Interventions
OTHERPancreatic adenocarcinoma diagnosis
Sponsors
University Hospital, Rouen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is male or female, and \> 18 years of age * Patient has a nonmetastatic solid pancreatic tumor (proved by CT thoraco-abdomino-pelvic) without histological evidence * Patient is referred for surgical treatment or biliopancreatic endoscopic ultrasound with fine needle aspiration (EUS-FNA) of a pancreatic mass * Patient has agree to participate by giving written informed consent
Exclusion criteria
* metastatic pancreatic tumor * cancer or other hematologic malignancy during treatment or in remission for less than 5 years. * minor patient under 18 years * contraindication to surgical treatment or contraindication to the biliopancreatic EUS-FNA * patient under guardianship * Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| sensitivity of circulating tumor cells for the diagnostic of pancreatic adenocarcinoma | Day 1 | Ratio between the numbers of patients for which CTCs were observed and patients with pancreatic adenocarcinoma confirmed by pathology (FNA OR surgical specimen) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| diagnostic performance of the circulating tumor DNA detection (KRAS) for the diagnosis of pancreatic adenocarcinoma | Day 1 | Sensitivity, specificity and diagnostic accuracy of the detection of circulating tumor DNA (KRAS mutation) for the diagnosis of pancreatic adenocarcinoma. |
| prognostic impact of circulating tumor cells and / or circulating tumor DNA (KRAS) and / or CA19.9 | Day 1 | Sensitivity, specificity and diagnostic accuracy of the combined detection of CTCs and circulating tumor DNA (KRAS mutation) for the diagnosis of pancreatic adenocarcinoma |
| Time to first recurrence or death | Month 36 | Time to first recurrence or death according to CTC and / or circulating tumor DNA and / or CA19.9 |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORDavid SEFRIOUI, MD
UH Rouen
Outcome results
None listed